| Factor . | LTNP-C (n = 242) . | Non-LTNP-C (n = 222) . | P; OR (95% CI) . | P; OR (95% CI) . |
|---|---|---|---|---|
| Unadjusted . | Adjusted . | |||
| Sex (male) | 197 (81.4) | 183 (82.1) | .774; .933 (.581–1.498) | |
| Age at HIV diagnosis (years) | 32 (26–38) | 35 (29–41) | .001; .965 (.945–.985) | .001; .962 (.942–.983) |
| Interferon-lambda 4 A/A genotype | 103 (42.6) | 121 (54.3) | .012; .625 (.433–.901) | .021; .637 (.434–.934) |
| HLA-B*27a | 53 (22.3) | 38 (17.9) | .253; 1.312 (.824–2.089) | |
| HLA-B*57a | 84 (35.3) | 47 (22.2) | .002; 1.915 (1.259–2.912) | .03; 1.924 (1.252–2.957) |
| HLA-B*35a | 23 (9.7) | 22 (10.4) | .801; .924 (.499–1.711) | |
| HLA-B*08a | 23 (9.7) | 26 (12.3) | .378; .765 (.422–1.387) |
| Factor . | LTNP-C (n = 242) . | Non-LTNP-C (n = 222) . | P; OR (95% CI) . | P; OR (95% CI) . |
|---|---|---|---|---|
| Unadjusted . | Adjusted . | |||
| Sex (male) | 197 (81.4) | 183 (82.1) | .774; .933 (.581–1.498) | |
| Age at HIV diagnosis (years) | 32 (26–38) | 35 (29–41) | .001; .965 (.945–.985) | .001; .962 (.942–.983) |
| Interferon-lambda 4 A/A genotype | 103 (42.6) | 121 (54.3) | .012; .625 (.433–.901) | .021; .637 (.434–.934) |
| HLA-B*27a | 53 (22.3) | 38 (17.9) | .253; 1.312 (.824–2.089) | |
| HLA-B*57a | 84 (35.3) | 47 (22.2) | .002; 1.915 (1.259–2.912) | .03; 1.924 (1.252–2.957) |
| HLA-B*35a | 23 (9.7) | 22 (10.4) | .801; .924 (.499–1.711) | |
| HLA-B*08a | 23 (9.7) | 26 (12.3) | .378; .765 (.422–1.387) |
Qualitative data are number (%) of individuals and quantitative data are median (interquartile range). Significant values are shown in bold.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; LTNP-C, long-term nonprogressor HIV-1 controller; OR, odds ratio.
aDominant model was applied. There were only 3 homozygous patients for HLA-B*57.
| Factor . | LTNP-C (n = 242) . | Non-LTNP-C (n = 222) . | P; OR (95% CI) . | P; OR (95% CI) . |
|---|---|---|---|---|
| Unadjusted . | Adjusted . | |||
| Sex (male) | 197 (81.4) | 183 (82.1) | .774; .933 (.581–1.498) | |
| Age at HIV diagnosis (years) | 32 (26–38) | 35 (29–41) | .001; .965 (.945–.985) | .001; .962 (.942–.983) |
| Interferon-lambda 4 A/A genotype | 103 (42.6) | 121 (54.3) | .012; .625 (.433–.901) | .021; .637 (.434–.934) |
| HLA-B*27a | 53 (22.3) | 38 (17.9) | .253; 1.312 (.824–2.089) | |
| HLA-B*57a | 84 (35.3) | 47 (22.2) | .002; 1.915 (1.259–2.912) | .03; 1.924 (1.252–2.957) |
| HLA-B*35a | 23 (9.7) | 22 (10.4) | .801; .924 (.499–1.711) | |
| HLA-B*08a | 23 (9.7) | 26 (12.3) | .378; .765 (.422–1.387) |
| Factor . | LTNP-C (n = 242) . | Non-LTNP-C (n = 222) . | P; OR (95% CI) . | P; OR (95% CI) . |
|---|---|---|---|---|
| Unadjusted . | Adjusted . | |||
| Sex (male) | 197 (81.4) | 183 (82.1) | .774; .933 (.581–1.498) | |
| Age at HIV diagnosis (years) | 32 (26–38) | 35 (29–41) | .001; .965 (.945–.985) | .001; .962 (.942–.983) |
| Interferon-lambda 4 A/A genotype | 103 (42.6) | 121 (54.3) | .012; .625 (.433–.901) | .021; .637 (.434–.934) |
| HLA-B*27a | 53 (22.3) | 38 (17.9) | .253; 1.312 (.824–2.089) | |
| HLA-B*57a | 84 (35.3) | 47 (22.2) | .002; 1.915 (1.259–2.912) | .03; 1.924 (1.252–2.957) |
| HLA-B*35a | 23 (9.7) | 22 (10.4) | .801; .924 (.499–1.711) | |
| HLA-B*08a | 23 (9.7) | 26 (12.3) | .378; .765 (.422–1.387) |
Qualitative data are number (%) of individuals and quantitative data are median (interquartile range). Significant values are shown in bold.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; LTNP-C, long-term nonprogressor HIV-1 controller; OR, odds ratio.
aDominant model was applied. There were only 3 homozygous patients for HLA-B*57.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
